N-benzyloxythalidomide | 600721-43-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: N-benzyloxythalidomide
• 英文别名: 2-(2,6-Dioxo-1-phenylmethoxypiperidin-3-yl)isoindole-1,3-dione
• CAS: 600721-43-5
• 化学式: C₂₀H₁₆N₂O₅
• 分子量: 364.357
• InChiKey: YKSNPWWRRJGNFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  84
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-benzyloxythalidomide 在 三乙基硅烷 、 aluminium amalgam 、 水 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 1-benzyloxy-3-(1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione
  参考文献：
  名称：

  Thalidomide Metabolites and Analogues. 3. Synthesis and Antiangiogenic Activity of the Teratogenic and TNFα-Modulatory Thalidomide Analogue 2-(2,6-Dioxopiperidine-3-yl)phthalimidine

  摘要：

  Versatile synthesis of the teratogenic, TNFalpha-modulatory, and antiangiogenic thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine (1) and its direct antiangiogenic properties are described. With thalidomide or thalidomide derivatives as precursors, the synthesis involved either carbonyl reduction/thiation-desulfurization or carbonyl reduction/acyliminium ion reduction protocols. Compared to earlier studies with thalidomide, which was only active with microsomal treatment, I exhibited marginal inhibitory activity in the rat aortic ring assay, thereby demonstrating the requirement for metabolic activation.

  DOI：

  10.1021/jm020079d
• 作为产物：
  描述：

  N-酞酰基-DL-谷氨酸酐 在 吡啶 、 乙酸酐 、 三氟乙酸酐 作用下， 反应 7.0h， 生成 N-benzyloxythalidomide
  参考文献：
  名称：

  Thalidomide Metabolites and Analogues. 3. Synthesis and Antiangiogenic Activity of the Teratogenic and TNFα-Modulatory Thalidomide Analogue 2-(2,6-Dioxopiperidine-3-yl)phthalimidine

  摘要：

  Versatile synthesis of the teratogenic, TNFalpha-modulatory, and antiangiogenic thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine (1) and its direct antiangiogenic properties are described. With thalidomide or thalidomide derivatives as precursors, the synthesis involved either carbonyl reduction/thiation-desulfurization or carbonyl reduction/acyliminium ion reduction protocols. Compared to earlier studies with thalidomide, which was only active with microsomal treatment, I exhibited marginal inhibitory activity in the rat aortic ring assay, thereby demonstrating the requirement for metabolic activation.

  DOI：

  10.1021/jm020079d

文献信息

• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR
  申请人：Arvinas, Inc.

  公开号：US20180099940A1

  公开（公告）日：2018-04-12

  The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

  本公开涉及双功能化合物，其用于降解和（抑制）雄激素受体。具体而言，本公开涉及包含一端结合到E3泛素连接酶的谷氨酰腺苷环配体，另一端结合到雄激素受体的部分的化合物，使得雄激素受体与泛素连接酶靠近，以实现雄激素受体的降解（和抑制）。本公开展示了与根据本公开涉及的化合物相关的广泛的药理活性范围，与雄激素受体的降解/抑制一致。
• Mono- and Dihydroxylated Metabolites of Thalidomide: Synthesis and TNF-.ALPHA. Production-Inhibitory Activity
  作者：Takanori Nakamura、Tomomi Noguchi、Hisayoshi Kobayashi、Hiroyuki Miyachi、Yuichi Hashimoto

  DOI：10.1248/cpb.54.1709

  日期：——

  Mono- and dihydroxylated metabolites of thalidomide were efficiently prepared and characterized, and their inhibitory activity on tumor necrosis factor (TNF)-α production in the human monocytic leukemia cell line THP-1 was evaluated. 5,N-Dihydroxythalidomide was a much more potent TNF-α production inhibitor than thalidomide.

  少量和双羟基化的沙利度胺代谢物被高效制备和表征，并评估了它们对人单核细胞白血病细胞系 THP-1 中肿瘤坏死因子 (TNF)-α 生产的抑制活性。5,N-二羟基沙利度胺是一种比沙利度胺更强效的 TNF-α 生产抑制剂。
• Enhancement of All-trans Retinoic Acid-Induced HL-60 Cell Differentiation by Thalidomide and Its Metabolites
  作者：Tomomi Noguchi、Chihiro Shinji、Hisayoshi Kobayashi、Makoto Makishima、Hiroyuki Miyachi、Yuichi Hashimoto

  DOI：10.1248/bpb.28.563

  日期：——

  Thalidomide (Thal: 1) and its two metabolites, 5-hydroxythalidomide (5-HT: 2) and N-hydroxythalidomide (N-HT: 3), showed an enhancing effect on all-trans retinoic acid (ATRA)-induced HL-60 cell differentiation. 5-HT and N-HT showed tubulin polymerization-inhibiting activity, but thalidomide did not.

  沙利度胺（Thal：1）及其两种代谢物，即5-羟基沙利度胺（5-HT：2）和N-羟基沙利度胺（N-HT：3），均显示出对全反式维甲酸（ATRA）诱导的HL-60细胞分化的增强作用。5-HT和N-HT具有抑制微管聚合的活性，而沙利度胺则没有这种作用。
• IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas, Inc.

  公开号：US20150291562A1

  公开（公告）日：2015-10-15

  The description relates to imide-based compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

  该描述涉及基于亚醰基的化合物，包括包含它们的双官能团化合物，这些化合物在靶向泛素化调节中发挥作用，特别是根据本发明的双官能团化合物抑制各种多肽和其他蛋白质的降解和/或抑制。具体来说，该描述提供了一种化合物，其中一端含有与小脑素E3泛素连接酶结合的配体，另一端含有结合目标蛋白的基团，使目标蛋白靠近泛素连接酶，以实现该蛋白的降解（和抑制）。可以合成表现出与几乎任何类型的靶向多肽的降解/抑制一致的广泛药理活性的化合物。
• Compounds and methods for the targeted degradation of androgen receptor
  申请人：Arvinas Operations, Inc.

  公开号：US10844021B2

  公开（公告）日：2020-11-24

  The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

  本公开涉及双功能化合物，它们可用于降解和（抑制）雄激素受体。特别是，本公开涉及的化合物一端含有与 E3 泛素连接酶结合的脑龙配体，另一端含有与雄激素受体结合的分子，这样雄激素受体就被置于泛素连接酶附近，从而实现对雄激素受体的降解（和抑制）。本公开的化合物具有广泛的药理活性，与雄激素受体的降解/抑制作用相一致。